id stringlengths 14 15 | text stringlengths 51 2.13k | source stringlengths 44 128 |
|---|---|---|
de14b5d1bbc9-0 | The cold chain describes the system of transporting and storing vaccines within the manufacturer’s recommended temperatures. It begins from when the vaccine is manufactured, transported through vaccine distribution centres, on to immunisation service providers and ends when the vaccine is administered.
Most vaccines ar... | mvec.mcri.edu.au/references/cold-chain-helpful-resources/index.html |
de14b5d1bbc9-1 | Ultra-cold chain handling equipment must be used as per manufacturer’s advice when handling frozen vaccines. Once frozen vaccines are defrosted, they cannot be refrozen.
For further information, refer to the Victorian COVID-19 vaccination guidelines.
Community pharmacy–acquired vaccines
The cold chain needs to be maint... | mvec.mcri.edu.au/references/cold-chain-helpful-resources/index.html |
de14b5d1bbc9-2 |
Resources
National Vaccine Storage Guidelines: Strive for 5
Department of Health – Cold Chain Management
Department of Health – Victorian COVID-19 vaccination guidelines
Author: Georgie Lewis (SAEFVIC Clinical Manager, Murdoch Children’s Research Institute)
Reviewed by: Rachael McGuire (MVEC Education Nurse Coordin... | mvec.mcri.edu.au/references/cold-chain-helpful-resources/index.html |
f32a118056d5-0 | What is it?
Typhoid and paratyphoid fever are bacterial infections, collectively known as enteric fever and are caused by the bacterias Salmonella enterica subspecies serovars Typhi and Paratyphi A, B and C. Enteric fever is different to the gastroenteritis that can be caused by Salmonella. Symptoms of enteric fever ca... | mvec.mcri.edu.au/references/typhoid/index.html |
f32a118056d5-1 | Epidemiology
Whilst not as prevalent in Australia, typhoid fever is a common infective illness in many parts of the world, especially Asia, southeast Asia and sub-Saharan Africa. There were 14.3 million cases of typhoid and paratyphoid fever in 2017, with an estimated global case fatality of 0.95%. Children are disprop... | mvec.mcri.edu.au/references/typhoid/index.html |
f32a118056d5-2 | §Whilst not registered for use in this age group, a number of travel medicine practitioners routinely administer Vivaxim® to children aged 2-15 years. Refer to Lau C. et al The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study Journal of Travel Medicine 2016:... | mvec.mcri.edu.au/references/typhoid/index.html |
f32a118056d5-3 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/typhoid/index.html |
0815aa2cc67b-0 | Background
One in 30 children will have a febrile seizure at some point during their childhood. They are typically triggered by a sudden rise in temperature, often as a result of a febrile illness. Febrile seizures more commonly occur in children between the ages of six months and six years, with a peak incidence ident... | mvec.mcri.edu.au/references/febrile-seizures-febrile-convulsions/index.html |
0815aa2cc67b-1 | Vaccine-proximate febrile seizures
Fever is a common side effect following vaccination with certain vaccines eg. meningococcal B, COVID-19, MMR, MMRV and influenza. Fever generally occurs within 48hrs of inactivated vaccines and 5-14 days after administration of live-attenuated vaccines.
Although vaccines can cause fev... | mvec.mcri.edu.au/references/febrile-seizures-febrile-convulsions/index.html |
0815aa2cc67b-2 | Recommendations
Prophylactic paracetamol
It is widely recognised that children receiving Bexsero (meningococcal B vaccine) are more likely to experience fevers following vaccination. It is for this reason that children < 4 years of age are recommended to receive prophylactic paracetamol prior to vaccination, as well as... | mvec.mcri.edu.au/references/febrile-seizures-febrile-convulsions/index.html |
0815aa2cc67b-3 | Features
Vaccination recommendations
Simple febrile seizure
Documented fever and all of the following:
generalised tonic-clonic seizure
≤ 15 minutes duration
no recurrence within 24 hours of initial seizure
complete recovery within 1 hour
no evidence of central nervous system infection
no previous neonatal or afebrile ... | mvec.mcri.edu.au/references/febrile-seizures-febrile-convulsions/index.html |
0815aa2cc67b-4 | Resources
CDC: Febrile seizures follwoing childhood vaccinations, including influenza vaccination
Epilepsy Foundation: Febrile seizures
Deng, L et. al, Seizures Following Vaccination in Children AJGP Vol 49, No 10, October 2020
RCH Clinical Practice Guidelines: Febrile seizure
RCH Kids Health Information: Febrile seizu... | mvec.mcri.edu.au/references/febrile-seizures-febrile-convulsions/index.html |
71414bc584d9-0 | There are a variety of factors that need to be considered in relation to the vaccination of the older population. A gradual decline of the immune system occurs as people age (known as immunosenescence), impacting how the immune system responds to new infections, as well as the effectiveness of long-term immune memory. ... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
71414bc584d9-1 | Zostavax®
Zostavax® has been shown to reduce the incidence of developing shingles by up to 50%, as well as the incidence of PHN in those ≥ 60 years of age by 66%. It is currently funded under the National Immunisation Program (NIP) for persons aged 70 years, with a catch-up program for those aged 71–79 years also funde... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
71414bc584d9-2 | Further guidance can be provided by reviewing the Australian Immunisation Handbook: Table. Live shingles vaccine (Zostavax) screening for contraindications or by contacting SAEFVIC prior to immunisation.
Pneumococcal vaccines
Invasive pneumococcal disease (IPD) can manifest as meningitis, pneumonia and bacteremia, with... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
71414bc584d9-3 | Influenza vaccines
For older adults, and those with certain medical conditions (eg. chronic lung disease, cardiac disease, immunosuppression), influenza disease can cause serious morbidity and mortality. Annual influenza vaccination is strongly encouraged and it is available for free on the NIP for those ≥ 65 years of ... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
71414bc584d9-4 | Considerations for residents of residential aged care facilities (RACF)
Whilst every effort should be made to immunise residents of RACF at risk of vaccine preventable diseases like COVID-19 and influenza, it is important to monitor for adverse events following immunisation (AEFIs). Due to a high incidence of cognitive... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
71414bc584d9-5 | Guidance for vaccination care of residents of Victorian Residential Aged Care Facilities
Aw D. Silva B. and Palmer D. Immunosenescence: emerging challenges for an ageing population Immunology 2007 Apr; 120(4): 435–446
Gustafson C. Kim C. Weyand C. Goronzy J Influence of immune aging on vaccine responses Journal of Alle... | mvec.mcri.edu.au/references/immunisation-recommendations-for-the-older-population/index.html |
ad3f5b5a39b6-0 | What is it?
The Western Health Immunisation Service at Joan Kirner Women and Children’s Hospital was established in July 2017. Run by immunisation nurses with the support of specialist paediatricians and infectious disease consultants, it is a walk-in clinic for patients and families of the hospital and local area. The... | mvec.mcri.edu.au/references/western-health-immunisation-service/index.html |
ad3f5b5a39b6-1 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/western-health-immunisation-service/index.html |
244faa855c2f-0 | MVEC is supportive of breastfeeding at the time of childhood immunisations as well as the immunisation of breastfeeding mothers when vaccines are indicated.
In this reference page, we detail the different types of vaccines recommended for breastfeeding women and describe when a more detailed discussion with your health... | mvec.mcri.edu.au/references/breastfeeding-and-immunisations/index.html |
244faa855c2f-1 | COVID-19 vaccines
Women who are breastfeeding can receive COVID-19 vaccines. They do not need to stop breastfeeding before or after being vaccinated. Antibodies have been detected in breastmilk and therefore this may also offer some protection to the infant via passive immunity.
Hepatitis B
It is safe for mothers who a... | mvec.mcri.edu.au/references/breastfeeding-and-immunisations/index.html |
244faa855c2f-2 | MVEC: COVID-19 vaccine FAQs: women’s health
Authors: Dr Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute), Rachael McGuire (MVEC Education Nurse Coordinator) and Georgina Lewis (Clinical Manager SAEFVIC, Murdoch Children’s Research Institute)
Reviewed by: Rachael McGuire (MVEC Education Nurse Coo... | mvec.mcri.edu.au/references/breastfeeding-and-immunisations/index.html |
fa0ba89f3d2c-0 | Background
Vaccines work by activating an individual’s immune system to form antibodies and memory cells in response to a pathogen (disease-causing organism), without the individual having to be infected with that pathogen. This means that if or when that pathogen is encountered in the future, the immune system will be... | mvec.mcri.edu.au/references/vaccine-platforms/index.html |
fa0ba89f3d2c-1 | Live-attenuated vaccines typically induce a strong immune response and provide long-lasting immunity meaning fewer doses are required. The main disadvantage of using this platform is that these vaccines are not recommended for use in people who are immunocompromised due to the theoretical risk of causing vaccine-associ... | mvec.mcri.edu.au/references/vaccine-platforms/index.html |
fa0ba89f3d2c-2 | Replicating viral vector vaccines have a similar mechanism but will also create new viral particles to enter further human cells, allowing a quicker and stronger immune response. Replicating viral vector vaccines best mimic natural infection and hence produce a strong immune response and can be used in lower doses.
Whi... | mvec.mcri.edu.au/references/vaccine-platforms/index.html |
fa0ba89f3d2c-3 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/vaccine-platforms/index.html |
c12b3f5d1b5d-0 | What is it?
Varicella (chickenpox) is a highly contagious infection caused by the varicella-zoster virus (VZV).
What to look for
Infection usually begins with 1-2 days of fever, runny nose and lethargy.
An itchy rash follows, involving fluid filled vesicles (blisters) that can cover any part of the body including insid... | mvec.mcri.edu.au/references/chickenpox/index.html |
c12b3f5d1b5d-1 | Neonates (whose mother develops infection up to 7 days prior to delivery or within 2 days after delivery), infants < 1-month of age (if mother is seronegative), pregnant women, premature infants (while still hospitalised, regardless of maternal serology) or immunosuppressed individuals who are exposed to varicella dise... | mvec.mcri.edu.au/references/chickenpox/index.html |
facf2e288bc7-0 | What is it?
Herpes zoster (shingles) is caused by a reactivation of the varicella zoster virus (VZV), the same virus that causes varicella (chickenpox) infection. After a person recovers from a varicella infection, the virus stays dormant (inactive) within the dorsal root ganglia of the spinal nerves but can later be r... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-1 | How is it transmitted?
Zoster cannot be passed from one person to another as it is the reactivation of that person’s previous VZV infection.
Exposure to the fluid-filled vesicles of a zoster rash can result in a VZV infection (as varicella infection) in a seronegative person (a person with no immunity to VZV). Zoster i... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-2 | Indications for use
Zostavax® is registered for use in adults aged ≥ 50 years and is provided on the National Immunisation Program (NIP) at 70 years of age (with a catch up program for those 71-79 years, ending 31st of October 2023). As it is a live-attenuated vaccine, Zostavax® is contraindicated in immunocompromised ... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-3 | Rarely, a non-localised VZV-like rash can occur 2-4 weeks following receipt of Zostavax®. Should this occur, medical attention is recommended for advice and management of symptoms which may include diagnostic testing and antiviral treatment. This event must also be reported to the relevant vaccine safety service (SAEFV... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-4 | Shingrix®
AdministrationImmunisation with Shingrix® requires a course of 2 dose course of 0.5ml given intramuscularly. Doses should be administered 2-6 months apart for immune competent individuals aged 50 years and over and 1-2 months apart for immunocompromised individuals ≥ 18 years of age.
Shingrix® can be co-admin... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-5 | Commonly asked questions
Can patients receive Shingrix® if they have previously been immunised with Zostavax®?Yes. An minimum interval of 12 months is recommended between receiving Zostavax® and the administration of Shingrix®. A 2 dose course of Shingrix® is still required.
Can patients receive Zostavax® if they have ... | mvec.mcri.edu.au/references/shingles/index.html |
facf2e288bc7-6 | Reviewed by: Rachael McGuire (MVEC Education Nurse Coordinator)
Date: April 4, 2023
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site t... | mvec.mcri.edu.au/references/shingles/index.html |
dccb8a406be1-0 | What is it?
Respiratory syncytial virus (RSV) is one of the leading causes of respiratory tract infections in young children. While for some it can cause the common cold, for others, it may lead to more severe infection. Children < 1 year of age, individuals with underlying medical conditions (e.g., chronic cardiac and... | mvec.mcri.edu.au/references/respiratory-syncytial-virus-rsv/index.html |
dccb8a406be1-1 | Synagis® (palivizumab) is an immunoglobulin (a blood product offering donated antibodies) currently available to some infants considered to be at higher risk of severe RSV disease (due to medical conditions such as prematurity, chronic lung disease, and specific cardiac conditions). It is not routinely available to all... | mvec.mcri.edu.au/references/respiratory-syncytial-virus-rsv/index.html |
a775c6e83aa8-0 | Background
Immunosuppression (also known as immunocompromise) occurs when a person’s immune system is weakened, resulting in a decreased ability to fight infections. Causes of immunosuppression may include having certain medical conditions (e.g., autoimmune disease, cancer, transplants, functional or anatomical aspleni... | mvec.mcri.edu.au/references/immunosuppression-and-vaccines/index.html |
a775c6e83aa8-1 | Influenza
Annual influenza vaccination is recommended for all immunosuppressed patients.
Those < 9 years of age are recommended to receive 2 doses of influenza vaccine, administered a minimum of 4 weeks apart, in the first year of receiving an influenza vaccine. Transplant recipients (solid organ or haematopoietic stem... | mvec.mcri.edu.au/references/immunosuppression-and-vaccines/index.html |
a775c6e83aa8-2 | COVID-19
COVID-19 vaccination is strongly recommended for all immunosuppressed individuals aged 6 months and over due to an increased risk of developing severe disease. A 3-dose primary course is recommended for optimal protection (compared with a 2-dose course for those who are immune competent). Following a primary ... | mvec.mcri.edu.au/references/immunosuppression-and-vaccines/index.html |
a775c6e83aa8-3 | ^routinely administered on the National Immunisation Program (NIP)
#recommended vaccine for select patient group only
¥available vaccine for those at higher risk of infection (eg. travel)
§not on NIP but available at cost
N/A no alternate vaccine available
Inadvertent administration of a live-attenuated vaccine
If an i... | mvec.mcri.edu.au/references/immunosuppression-and-vaccines/index.html |
a775c6e83aa8-4 | It is safe for household contacts to receive live-attenuated vaccines (including rotavirus and varicella). Thorough hand hygiene should always be performed when handling soiled nappies of rotavirus vaccine recipients to minimise the risk of vaccine-virus transmission. Any varicella-like blisters that occur on the vacci... | mvec.mcri.edu.au/references/immunosuppression-and-vaccines/index.html |
7bb21e75c25f-0 | The Paediatric Active Enhanced Disease Surveillance (PAEDS) network is a hospital-based active surveillance system employing prospective case ascertainment for selected serious childhood conditions, particularly vaccine preventable diseases and potential adverse events following immunisation (AEFI). PAEDS data is used ... | mvec.mcri.edu.au/references/paeds-paediatric-active-enhanced-disease-surveillance/index.html |
7bb21e75c25f-1 | Invasive Group A Streptococcus (A severe bacterial infection)
Kawasaki Disease (rare disease in which blood vessels throughout the body become inflamed)
Gram Negative Bloodstream Infections (serious bacterial infections in the bloodstream)
COVID-19 (SARS-CoV-2)
PIMS-TS (Paediatric Inflammatory Multisystem Syndrome temp... | mvec.mcri.edu.au/references/paeds-paediatric-active-enhanced-disease-surveillance/index.html |
c7ddbe0ab158-0 | Background
Guillain-Barre Syndrome (GBS) is an autoimmune condition whereby the body’s own immune system can attack the nerves, damaging the myelin (insulating layer) and sometimes the axon (nerve fiber). This damage can result in symptoms of muscle weakness, altered sensation, numbness and paralysis.
The rate of GBS i... | mvec.mcri.edu.au/references/guillain-barre-syndrome/index.html |
c7ddbe0ab158-1 | GBS and meningococcal vaccines
There is no increased risk of developing GBS after receiving meningococcal vaccinations. People with a history of GBS can safely receive meningococcal vaccines. It is also safe for them to receive all of the other routine National Immunisation Program (NIP) and travel vaccines as required... | mvec.mcri.edu.au/references/guillain-barre-syndrome/index.html |
c7ddbe0ab158-2 | Reviewed by: Rachael McGuire (MVEC Education Nurse Coordinator)
Date: November 29, 2022
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this si... | mvec.mcri.edu.au/references/guillain-barre-syndrome/index.html |
dfeb85b926d1-0 | What is it?
Measles, also known as rubeola, is a highly contagious viral illness. It is caused by the measles virus which belongs to the Morbillivirus family.
What to look for
Infection usually begins with 3-4 days of fever, malaise, cough, coryza (runny nose) and conjunctivitis. Small white spots, known as Koplik spot... | mvec.mcri.edu.au/references/measles/index.html |
dfeb85b926d1-1 | The incubation period is 7 to 18 days (more commonly 10 days), with a person able to transmit disease for up to 5 days prior to the onset of the rash, and as long as 4 days after the rash develops.
Humans are the only reservoirs for the measles virus.
Epidemiology
Prior to the introduction of vaccination in 1963, measl... | mvec.mcri.edu.au/references/measles/index.html |
dfeb85b926d1-2 | Contraindications
Live-attenuated vaccines such as measles-containing vaccines are contraindicated in individuals with immune compromise due to the risks of adverse events and the chance of developing vaccine-related disease.
Additionally, pregnant women should not receive measles-containing vaccines due to the potenti... | mvec.mcri.edu.au/references/measles/index.html |
dfeb85b926d1-3 | Australian Immunisation Handbook: Table: Recommended intervals between immunoglobulins or blood products, and measles-mumps-rubella, measles-mumps-rubella-varicella or varicella vaccination
World Health Organization: measles
MVEC: MMR vaccine and autism
RCH Clinical Practice Guideline: illness in the returned traveller... | mvec.mcri.edu.au/references/measles/index.html |
c1a0f6c164a5-0 | AEFI-CAN (Adverse Events Following Immunisation – Clinical Assessment Network) is a formal collaboration between Australian state and territory-based vaccine safety clinics and their adult and paediatric immunisation/infectious diseases/allergy specialists. It also includes representatives from the Therapeutic Goods Ad... | mvec.mcri.edu.au/references/aefi-can-adverse-events-following-immunisation-clinical-assessment-network/index.html |
8e0196e42c23-0 | Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune cond... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-1 | International and local vaccine safety surveillance data have found that it is more commonly associated with administration of a second dose of COVID-19 mRNA vaccine. Myocarditis following other COVID-19 vaccines, third doses or booster doses have also been identified, although reported cases have occurred at lower rat... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-2 | coronary artery disease
myocardial infarction
stable heart failure
arrhythmias
rheumatic fever
rheumatic heart disease
kawasaki disease
most congenital heart disease
those with implanted cardiac devices
congenital heart disease
cardiac transplant
cardiomyopathy.
Those with a history of the following conditions can also... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-3 | electrocardiogram (ECG).
Other tests should be considered if the patient is unwell or the tests above are abnormal:
chest X-ray (CXR)
other tests related to investigating differential diagnoses such as inflammatory markers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
bedside or formal ultrasound/e... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-4 | What are the implications for future doses (including third and booster doses)?For individuals where the cause of inflammation is attributed to COVID-19 vaccination, a report to SAEFVIC is indicated and a referral to a cardiologist and/or specialist immunisation service (eg. VicSIS) is recommended.
Please refer to the ... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-5 | Reported rates of pericarditis occurring following administration of a COVID-19 vaccine vary; however, they are above expected background population rates. Available surveillance data suggests the risks for pericarditis after a mRNA vaccine are higher than non-mRNA vaccines.
International and local data indicate that p... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-6 | those with implanted cardiac devices
congenital heart disease
cardiac transplant
cardiomyopathy.
Those with a history of the following conditions can also receive COVID-19 vaccines; however should consult their treating specialist to determine the appropriate timing for vaccination:
recent (within 3 months) or current ... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-7 | Consistent findings of pericarditis include a pericardial rub on auscultation, widespread ST-elevation or PR depression on ECG, as well as pericardial effusion on imaging.
Individuals who are investigated for pericarditis following vaccination should avoid high-intensity exercise until symptoms have resolved is recomme... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-8 | Access a pdf version of this guide here.
In particular, the groups which are at lower risk (green in algorithm), could proceed with further doses of COVID-19 vaccination as per above suggested instructions.
What is the risk/benefit ratio for vaccination for the young adult age group?It is important to discuss your indi... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-9 | Should exercise be limited after receiving COVID-19 vaccines to reduce the chance of myocarditis/pericarditis?Exercise is not thought to increase the risk of developing myocarditis/pericarditis following COVID-19 vaccination. It is therefore not necessary to reduce or avoid exercise in the post-vacccination period.
How... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
8e0196e42c23-10 | MVEC COVID-19 vaccine FAQs: mRNA vaccines: myocarditis/pericarditis
Authors: Rachael McGuire (MVEC Education Nurse Coordinator), Francesca Machingaifa (MVEC Education Nurse Coordinator), Daryl Cheng (MVEC Medical Lead) and Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute)
Reviewed by: Daryl Cheng... | mvec.mcri.edu.au/references/pericarditis-and-myocarditis-following-covid-19-vaccines/index.html |
da63b7e17e68-0 | Drive-through immunisation clinics are an alternative venue for supporting vaccine delivery. A drive-through clinic can assist members of the community to continue to receive recommended immunisations whilst maintaining physical distancing.
A drive-through clinic may not be a setting that is recommended for all patient... | mvec.mcri.edu.au/references/how-to-set-up-a-drive-through-immunisation-clinic/index.html |
da63b7e17e68-1 | Staff may include nurse immunisers, as well as medical and administrative personnel.
The cold chain
Storage of vaccines in a drive-through clinic setting must comply with the cold chain recommendations set out by the vaccine manufacturer. The time between vaccines being removed from purpose-built vaccine fridges to be... | mvec.mcri.edu.au/references/how-to-set-up-a-drive-through-immunisation-clinic/index.html |
da63b7e17e68-2 | ATAGI Clinical Statement on Vaccination Observation Time
ATAGI statement on considerations for establishing drive-through COVID-19 vaccination clinic sites
Authors: Francesca Machingaifa (SAEFVIC Research Nurse, Murdoch Children’s Research Institute) and Rachael McGuire (SAEFVIC Research Nurse, Murdoch Children’s Resea... | mvec.mcri.edu.au/references/how-to-set-up-a-drive-through-immunisation-clinic/index.html |
8321e1c062e2-0 | Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune cond... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-1 | International and local vaccine safety surveillance data have found that it is more commonly associated with administration of a second dose of COVID-19 mRNA vaccine. Myocarditis following other COVID-19 vaccines, third doses or booster doses have also been identified, although reported cases have occurred at lower rat... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-2 | coronary artery disease
myocardial infarction
stable heart failure
arrhythmias
rheumatic fever
rheumatic heart disease
kawasaki disease
most congenital heart disease
those with implanted cardiac devices
congenital heart disease
cardiac transplant
cardiomyopathy.
Those with a history of the following conditions can also... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-3 | electrocardiogram (ECG).
Other tests should be considered if the patient is unwell or the tests above are abnormal:
chest X-ray (CXR)
other tests related to investigating differential diagnoses such as inflammatory markers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
bedside or formal ultrasound/e... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-4 | What are the implications for future doses (including third and booster doses)?For individuals where the cause of inflammation is attributed to COVID-19 vaccination, a report to SAEFVIC is indicated and a referral to a cardiologist and/or specialist immunisation service (eg. VicSIS) is recommended.
Please refer to the ... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-5 | Reported rates of pericarditis occurring following administration of a COVID-19 vaccine vary; however, they are above expected background population rates. Available surveillance data suggests the risks for pericarditis after a mRNA vaccine are higher than non-mRNA vaccines.
International and local data indicate that p... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-6 | those with implanted cardiac devices
congenital heart disease
cardiac transplant
cardiomyopathy.
Those with a history of the following conditions can also receive COVID-19 vaccines; however should consult their treating specialist to determine the appropriate timing for vaccination:
recent (within 3 months) or current ... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-7 | Consistent findings of pericarditis include a pericardial rub on auscultation, widespread ST-elevation or PR depression on ECG, as well as pericardial effusion on imaging.
Individuals who are investigated for pericarditis following vaccination should avoid high-intensity exercise until symptoms have resolved is recomme... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-8 | Access a pdf version of this guide here.
In particular, the groups which are at lower risk (green in algorithm), could proceed with further doses of COVID-19 vaccination as per above suggested instructions.
What is the risk/benefit ratio for vaccination for the young adult age group?It is important to discuss your indi... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-9 | Should exercise be limited after receiving COVID-19 vaccines to reduce the chance of myocarditis/pericarditis?Exercise is not thought to increase the risk of developing myocarditis/pericarditis following COVID-19 vaccination. It is therefore not necessary to reduce or avoid exercise in the post-vacccination period.
How... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
8321e1c062e2-10 | MVEC COVID-19 vaccine FAQs: mRNA vaccines: myocarditis/pericarditis
Authors: Rachael McGuire (MVEC Education Nurse Coordinator), Francesca Machingaifa (MVEC Education Nurse Coordinator), Daryl Cheng (MVEC Medical Lead) and Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute)
Reviewed by: Daryl Cheng... | mvec.mcri.edu.au/references/myocarditis-and-pericarditis-following-covid-19-vaccines/index.html |
93b91d5f33dc-0 | Each local council throughout Victoria offers regular immunisation sessions for the administration of all funded National Immunisation Program (NIP) vaccines. Sessions are free to attend and people of all ages requiring NIP vaccines can be vaccinated. Sessions are run by accredited nurse immunisers with medical support... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
93b91d5f33dc-1 | Dandenong immunisation session times
Hobsons Bay City Council
(03) 9932 1000
Hobsons Bay immunisation session times
Hume City Council
(03) 9205 2200
Hume immunisation session times
Kingston City Council
1300 653 356
Kingston immunisation session times
Knox City Council
(03) 9298 8000
Knox immunisation session times
Man... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
93b91d5f33dc-2 | Stonnington immunisation session times
Whitehorse City Council
(03) 9262 6197
Whitehorse immunisation session times
Whittlesea City Council
(03) 9217 2170
Whittlesea immunisation session times
Wyndham City Council
(03) 9742 0777
Wyndham immunisation session times
Yarra City Council
(03) 9205 5555
Yarra City immunisatio... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
93b91d5f33dc-3 | Corangamite Shire Council
(03) 5232 7100
Corangamite immunisation session times
East Gippsland Shire Council
(03) 5153 9500
East Gippsland immunisation session times
Gannawarra Shire Council
(03) 5450 9333
Gannawarra immunisation session times
Glenelg Shire Council
(03) 5522 2211
Glenelg immunisation session times
Gold... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
93b91d5f33dc-4 | (03) 5775 8555
Mansfield immunisation session times
Mildura Rural City Council
(03) 5018 8100
Mildura immunisation session times
Mitchell Shire Council
(03) 5734 6200
Mitchell immunisation session times
Moira Shire Council
(03) 5871 9222
Moira immunisation session times
Moorabool Shire Council
(03) 5366 7100
Moorabool ... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
93b91d5f33dc-5 | (02) 6071 5100
Towong immunisation session times
Rural City of Wangaratta
(03) 5722 0888
Wangaratta immunisation session times
Warrnambool City Council
(03) 5559 4855
Warrnambool immunisation session times
Wellington Shire Council
1300 366 244
Wellington immunisation session times
West Wimmera Shire Council
(03) 5585 9... | mvec.mcri.edu.au/references/victorian-council-immunisation-sessions/index.html |
0abbcb462246-0 | Background
The International Network of Special Immunization Services (INSIS) is a coordinated international collaboration of vaccine safety surveillance systems. By collaborating on a global scale, rare serious adverse events following immunisation (occurring in < 1 per 10,000 vaccine recipients) are more likely to be... | mvec.mcri.edu.au/references/international-network-of-special-immunization-services/index.html |
0abbcb462246-1 | Date: March 9, 2023
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal hea... | mvec.mcri.edu.au/references/international-network-of-special-immunization-services/index.html |
f67ab234adbf-0 | There are a number of neurological conditions that are associated with an increased risk of vaccine preventable diseases. These include:
Epilepsy and seizure disorders
Developmental delay and intellectual disability
Cerebral palsy
Neuromuscular disorders
Hydrocephalus and children with ventricular-peritoneal shunts
Chi... | mvec.mcri.edu.au/references/neurologic-and-neurodevelopmental-conditions/index.html |
f67ab234adbf-1 | There is some evidence for potential virus transmission via viral particles on hands.
HPV infection is associated with the potential development of serious disease such as cervical and anogenital cancers. The infection is also the primary cause of anogenital warts.
As transmission can be varied, children with neurodeve... | mvec.mcri.edu.au/references/neurologic-and-neurodevelopmental-conditions/index.html |
b543c4224852-0 | The Victorian Specialist Immunisation Services (VicSIS) network was established in 2021 to help support the COVID-19 vaccine rollout in Victoria. It was coordinated and funded by the Victorian Department of Health (DH) with clinical support provided by SAEFVIC (the Victorian vaccine safety service).
VicSIS provided s... | mvec.mcri.edu.au/references/the-vicsis-victorian-specialist-immunisation-services-network/index.html |
bedabf4fe3c8-0 | What is it?
Individuals that are at higher risk of vaccine preventable diseases (VPD) are classified as ‘special risk’ groups in the Australian Immunisation Handbook.
This includes populations at special risk (e.g. Aboriginal and Torres Straight Islanders) and those with additional vaccine requirements (e.g. maternal v... | mvec.mcri.edu.au/references/special-risk-chapter-in-the-australian-immunisation-handbook/index.html |
5f18c03c265a-0 | What is it?
Kawasaki disease (KD) is the second most common form of vasculitis (inflammation of blood vessels) in childhood, affecting 200-300 Australian children every year. It mostly occurs in children aged under 5, with some rare cases affecting older children or adults. KD is a collection of symptoms including pers... | mvec.mcri.edu.au/references/kawasaki-disease-and-vaccines/index.html |
5f18c03c265a-1 | Live-attenuated vaccines such as measles-mumps-rubella-varicella and measles-mumps-rubella must be delayed 11 months following the administration of intravenous immunoglobulin (IVIg) as the transfusion of IVIg can affect the immune response to the vaccine.
Resources
MVEC: Live-attenuated vaccines and immunoglobulins or... | mvec.mcri.edu.au/references/kawasaki-disease-and-vaccines/index.html |
1403e2188b38-0 | The development of a nodule at the injection site is a known but rare adverse event following immunisation (AEFI). Nodules are defined as the presence of a palpable, firm, discrete or well-demarcated soft tissue lump at the site of immunisation in the absence of heat, erythema (redness) or signs of abscess.
Nodules can... | mvec.mcri.edu.au/references/injection-site-nodules/index.html |
1403e2188b38-1 | Rare or persisting subcutaneous nodules
Some nodules can become symptomatic and last for months or even years and are referred to as persisting subcutaneous nodules. Pruritus (itch) is the most concerning symptom that motivates parents to seek medical attention. Ongoing pruritus can alter the appearance of the skin lea... | mvec.mcri.edu.au/references/injection-site-nodules/index.html |
1403e2188b38-2 | Bergfors, E. Lundmark, K. Kronander, U. A child with a long-standing, intensely itching subcutaneous nodule on a thigh: an uncommon (?) reaction to commonly used vaccines, BMJ Case Reports 2013:bcr2012007779
MVEC: Injection site reactions
Authors: Mel Addison (SAEFVIC Research Nurse, Murdoch Children’s Research Institu... | mvec.mcri.edu.au/references/injection-site-nodules/index.html |
975e7566ee29-0 | Background
Pneumococcal disease is caused by Streptococcus Pneumoniae (pneumococcus), a bacteria that can live in the nose and throat (nasopharynx) of healthy people and in most cases does not cause illness or disease. However, in some cases the bacteria may grow and spread to other parts of the body. Invasive pneumoc... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
975e7566ee29-1 | Pneumovax 23® (23vPPV) – a polysaccharide vaccine, providing protection against 23 serotypes of pneumococcal (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F). It is available on the NIP as an additional recommendation for individuals >4-years of age who are at increas... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
975e7566ee29-2 | injection site reactions (redness, heat, swelling and tenderness)
body aches
Note – In children, injection site reactions are more commonly reported as occurring within 24-48 hours following immunisation. In adults, injection site reactions may occur >3 days following the 13vPCV dose given at >70years, particularly in ... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
975e7566ee29-3 | < 12-months
As per NIP (2, 4 & 12-months) + 1 additional dose at 6-months^ (total 4 doses in a lifetime)
Dose 1 at 4-years of age
Dose 2 ≥ 5-years following dose 1*
≥ 12-months
As per NIP (2, 4 & 12-months) + 1 additional dose at age of diagnosis,^ given a minimum of 2-months after dose 3 (total 4 doses in a lifetime)
... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
975e7566ee29-4 | *Maximum amount of 23vPPV in a lifetime is 2 doses
^ Refer to specific pneumococcal catch up advice if commencing immunisations late/delayed including Table. Catch-up schedule for 13vPCV for Aboriginal and Torres Strait Islander children living in NSW, Vic, Tas or ACT, and all children who do not have risk condition(s)... | mvec.mcri.edu.au/references/pneumococcal-disease-and-vaccines/index.html |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 7